What Researchers Did
Researchers conducted a retrospective review of 22 prostate cancer patients with radiation-induced hematuria who underwent hyperbaric oxygen therapy between April 2000 and March 2010 to identify factors associated with hematuria resolution.
What They Found
Overall, 11 out of 22 men (50%) experienced resolution of hematuria after hyperbaric oxygen therapy, with a median follow-up of 2.2 years. The Radiation Therapy Oncology Group (RTOG) grade of hematuria was found to be predictive of whether hematuria resolved or persisted after treatment (p = 0.026).
What This Means for Canadian Patients
Canadian patients with radiation-induced hematuria from prostate cancer treatment may benefit from understanding that the initial severity of their hematuria could influence the effectiveness of hyperbaric oxygen therapy. This insight can help patients and their doctors make more informed decisions about pursuing this treatment option.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or with Canadian participants.
Study Limitations
As a retrospective study with a small sample size of 22 men, the findings may be subject to selection bias and limited generalizability.